Pharmacogenomics of antimicrobial agents

Ar Kar Aung, David W Haas, Todd Hulgan, Elizabeth J Phillips

Research output: Contribution to journalReview ArticleResearchpeer-review

12 Citations (Scopus)

Abstract

Antimicrobial efficacy and toxicity varies between individuals owing to multiple factors. Genetic variants that affect drug-metabolizing enzymes may influence antimicrobial pharmacokinetics and pharmacodynamics, thereby determining efficacy and/or toxicity. In addition, many severe immune-mediated reactions have been associated with HLA class I and class II genes. In the last two decades, understanding of pharmacogenomic factors that influence antimicrobial efficacy and toxicity has rapidly evolved, leading to translational success such as the routine use of HLA-B∗57:01 screening to prevent abacavir hypersensitivity reactions. This article examines recent advances in the field of antimicrobial pharmacogenomics that potentially affect treatment efficacy and toxicity, and challenges that exist between pharmacogenomic discovery and translation into clinical use. © 2014 Future Medicine Ltd.
Original languageEnglish
Pages (from-to)1903-1930
Number of pages28
JournalPharmacogenomics
Volume15
Issue number15
DOIs
Publication statusPublished - 2014
Externally publishedYes

Keywords

  • antibacterials
  • antifungals
  • antimalarials
  • antivirals
  • pharmacogenomics

Cite this